Log in

Affimed Stock Price, News & Analysis (NASDAQ:AFMD)

$2.74
+0.09 (+3.40 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$2.68
Now: $2.74
$2.77
50-Day Range
$2.64
MA: $2.99
$3.71
52-Week Range
$2.52
Now: $2.74
$5.08
Volume256,108 shs
Average Volume681,417 shs
Market Capitalization$170.95 million
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2167-4360

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.03 million
Book Value$0.76 per share

Profitability

Net Income$-23,000,000.00

Miscellaneous

Employees8,406
Market Cap$170.95 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.


Affimed (NASDAQ:AFMD) Frequently Asked Questions

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) released its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.16). The biopharmaceutical company earned $4.50 million during the quarter, compared to the consensus estimate of $6.46 million. Affimed had a negative return on equity of 30.94% and a negative net margin of 30.87%. View Affimed's Earnings History.

When is Affimed's next earnings date?

Affimed is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Affimed.

What price target have analysts set for AFMD?

3 brokerages have issued 1 year price objectives for Affimed's stock. Their forecasts range from $4.17 to $10.00. On average, they anticipate Affimed's share price to reach $7.39 in the next twelve months. This suggests a possible upside of 169.7% from the stock's current price. View Analyst Price Targets for Affimed.

What is the consensus analysts' recommendation for Affimed?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.

Has Affimed been receiving favorable news coverage?

Media headlines about AFMD stock have trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Affimed earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Affimed.

Are investors shorting Affimed?

Affimed saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 5,580,000 shares, a decline of 10.0% from the August 30th total of 6,200,000 shares. Based on an average trading volume of 580,400 shares, the days-to-cover ratio is presently 9.6 days. Currently, 11.0% of the shares of the stock are short sold. View Affimed's Current Options Chain.

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

Who are Affimed's key executives?

Affimed's management team includes the folowing people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
  • Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
  • Prof. Melvyn Little, Founder & Consultant
  • Dr. Martin Treder, Chief Scientific Officer (Age 49)

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.74.

How big of a company is Affimed?

Affimed has a market capitalization of $170.95 million and generates $28.03 million in revenue each year. The biopharmaceutical company earns $-23,000,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Affimed employs 8,406 workers across the globe.View Additional Information About Affimed.

What is Affimed's official website?

The official website for Affimed is http://www.affimed.com/.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]


MarketBeat Community Rating for Affimed (NASDAQ AFMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  357 (Thanks for Voting!)
Underperform Votes:  249 (Thanks for Voting!)
Total Votes:  606
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel